1. Home
  2. UGRO vs OGEN Comparison

UGRO vs OGEN Comparison

Compare UGRO & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo urban-gro Inc.

UGRO

urban-gro Inc.

HOLD

Current Price

$0.31

Market Cap

3.0M

ML Signal

HOLD

Logo Oragenics Inc.

OGEN

Oragenics Inc.

HOLD

Current Price

$0.91

Market Cap

3.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UGRO
OGEN
Founded
2014
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.0M
3.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
UGRO
OGEN
Price
$0.31
$0.91
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$3.00
N/A
AVG Volume (30 Days)
3.0M
84.3K
Earning Date
03-27-2026
11-07-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$59,985,138.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$28.40
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.21
$0.82
52 Week High
$1.26
$18.90

Technical Indicators

Market Signals
Indicator
UGRO
OGEN
Relative Strength Index (RSI) 58.69 40.04
Support Level $0.23 $0.85
Resistance Level $0.25 $1.00
Average True Range (ATR) 0.04 0.07
MACD 0.01 0.01
Stochastic Oscillator 49.57 33.64

Price Performance

Historical Comparison
UGRO
OGEN

About UGRO urban-gro Inc.

Urban-gro Inc is an integrated professional services and construction design-build firm. Its business focuses predominantly on providing fee-based knowledge-based services as well as the value-added reselling of equipment. The company offers value-added architectural, engineering, systems procurement and integration, and construction design-build solutions to customers operating in the controlled environment agriculture (CEA) and industrial and other commercial (Commercial) sectors. It derives revenue predominately from the sale of equipment systems, services, construction design-build, and other various immaterial contracts with customers.

About OGEN Oragenics Inc.

Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.

Share on Social Networks: